|
Pacritinib Clinical Trials
8 actively recruiting trials across 6 locations
Also known as: 937272-79-2, Oral JAK2 Inhibitor SB1518, Pacritinib Citrate, SB 1518, SB-1518, SB1518, VONJO, vonjo
Duarte, California2 trials
Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
City of Hope Medical Center
Phase 1
Phase 2
Seattle, Washington2 trials
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
Fred Hutch/University of Washington Cancer Consortium
Phase 2
Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms
Fred Hutch/University of Washington Cancer Consortium
Phase 2
Tampa, Florida1 trial
Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
Moffitt Cancer Center
Phase 2
Boston, Massachusetts1 trial
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
Dana Farber Cancer Institute
Phase 2
New York, New York1 trial
Pacritinib in CMML
The Mount Sinai Hospital
Phase 1/2
Philadelphia, Pennsylvania1 trial
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
Fox Chase Cancer Center - Philadelphia
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.